259 related articles for article (PubMed ID: 11683686)
1. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2001 Nov; 15(11):1729-36. PubMed ID: 11683686
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Edwards SJ; Lind T; Lundell L; DAS R
Aliment Pharmacol Ther; 2009 Sep; 30(6):547-56. PubMed ID: 19558609
[TBL] [Abstract][Full Text] [Related]
6. Review of esomeprazole in the treatment of acid disorders.
Johnson DA
Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
10. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Labenz J; Armstrong D; Leodolter A; Baldycheva I
Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
[TBL] [Abstract][Full Text] [Related]
11. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
Thitiphuree S; Talley NJ
Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
14. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
[TBL] [Abstract][Full Text] [Related]
16. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Yaghoobi M; Padol S; Yuan Y; Hunt RH
Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
18. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis.
Vakil N
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():21-3. PubMed ID: 12614303
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
20. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
